Key Updates Needed in Chronic Spontaneous Urticaria Guidelines

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who are difficult to treat.

Patients with chronic spontaneous urticaria experienced a long delay in diagnosis, a substantial impact on their quality of life, and often received inadequate treatment, highlighting the need for better management and understanding of the condition.

Raj Chovatiya, MD, PhD, MSCI, highlights promising research in atopic dermatitis focused on identifying patient subgroups for targeted treatments and achieving long-term remission.

US migrant populations experience various dermatologic conditions linked to exposures before, during, and after migration, often exacerbated by barriers to accessing health care.

Research presented at the 2025 Academy of Managed Care Pharmacy annual meeting analyzed real-world treatment outcomes for dermatologic conditions, specifically highlighting the efficacy of ruxolitinib cream for atopic dermatitis and the potential for phototherapy to delay costly biologic initiation.

The long-term safety and efficacy of omalizumab, alongside promising phase 3 trial results that demonstrated the efficacy and favorable hematological safety profile of remibrutinib, were highlighted at the 2025 American Academy of Allergy, Asthma & Immunology/World Allergy Organization Joint Congress.